Yubo International Biotech Ltd financial data

Symbol
YBGJ on OTC
Industry
Electromedical & Electrotherapeutic Apparatus
Location
Room 105, Building 5, 31 Xishiku Avenue, Beijing, China
State of incorporation
NY
Fiscal year end
December 31
Former names
MAGNA LAB INC (to 12/4/2020)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 19.2 % -24.9%
Quick Ratio 3.39 % -61.6%
Debt-to-equity -167 % +49.1%
Return On Equity 91.7 % +45.9%
Return On Assets -130 % -372%
Operating Margin -8.93K % -10063%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares
Entity Public Float 2.98M USD +4042%
Weighted Average Number of Shares Outstanding, Diluted 120M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 21.6K USD -96.7%
Operating Income (Loss) -1.93M USD -236%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.15M USD -274%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -2.15M USD -274%
Earnings Per Share, Diluted -0.01 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.03K USD +51.7%
Inventory, Net 6.57K USD -96.9%
Assets, Current 724K USD +1.64%
Property, Plant and Equipment, Net 257K USD -51.4%
Operating Lease, Right-of-Use Asset 579K USD +18.1%
Intangible Assets, Net (Excluding Goodwill) 56.1K USD +0.88%
Assets 1.65M USD -13.1%
Liabilities, Current 4.49M USD +56.7%
Operating Lease, Liability, Noncurrent 206K USD +47.8%
Liabilities 4.7M USD +56.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 132K USD -38%
Retained Earnings (Accumulated Deficit) -6.37M USD -45.9%
Stockholders' Equity Attributable to Parent -3.13M USD -184%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -3.04M USD -176%
Liabilities and Equity 1.65M USD -13.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -120K USD -269%
Net Cash Provided by (Used in) Financing Activities 98K USD
Net Cash Provided by (Used in) Investing Activities -30K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.7K USD +322%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.03K USD +51.7%
Deferred Tax Assets, Valuation Allowance 1.45M USD +59.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.17 pure 0%
Operating Lease, Liability 579K USD
Payments to Acquire Property, Plant, and Equipment 18.9K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.24M USD -1398%
Lessee, Operating Lease, Liability, to be Paid 618K USD +23%
Property, Plant and Equipment, Gross 279K USD -50.7%
Operating Lease, Liability, Current 373K USD +6.28%
Lessee, Operating Lease, Liability, to be Paid, Year Two 114K USD -59.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 390K USD +283%
Lessee, Operating Lease, Liability, to be Paid, Year Three 17K USD -83.3%
Deferred Tax Assets, Operating Loss Carryforwards 1.45M USD
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -102K USD -29.3%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 17K USD
Additional Paid in Capital 2.99M USD +1.85%
Operating Leases, Future Minimum Payments, Due in Two Years 843K USD +51.6%
Amortization of Intangible Assets 13.3K USD +12.3%
Depreciation, Depletion and Amortization 243K USD +4.05%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 2.67M USD -6.72%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Operating Leases, Future Minimum Payments, Due in Three Years 748K USD +34.5%
Interest Expense 49 USD -62.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%